Best Read Articles on Biosimilars in 2021
News about interchangeable Semglee (insulin glargine-yfgn) was among the most read in 2021.
Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
Read more
OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary
OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.
Read more
Survey: Biosimilars are Gaining Momentum Among Payers
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
Walgreens Offering Biosimilar and Interchangeable Insulin Semglee
Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.
Study: Medicare Part B Reimbursement Hinders Biosimilar Uptake
A reimbursement policy similar to that used for branded and generic drugs would have saved $1.6 billion from 2015 to 2019.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
